Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
Study Details
Study Description
Brief Summary
To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Eribulin in combination with anti-PD-1 antibody Participants receive eribulin1.4mg/m2 and anti-PD-1 antibody intravenously (IV) every 3 weeks (Q3W) . |
Drug: Eribulin
Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
Other Names:
Drug: anti-PD-1 antibody
Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
|
Outcome Measures
Primary Outcome Measures
- Progression Free Survival，PFS [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months]
The time from the date of randomization to the date of first documented progression or date of death from any cause, whichever came first.
Secondary Outcome Measures
- Number of participants with Adverse Events [From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months]
Adverse Events are monitored throughout the trial and for 30 days after discontinuation of treatment (90 days for serious adverse events) and graded according to the Common Terminology Criteria for Adverse Events, version 4.0, of the National Cancer Institute.
- the correlation between the expression of PD-L1 of circulating tumor cells and prognosis [From one week before treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months]
To detect the differences of the expression of PD-L1 in patients with different curative effects and prognosis,including the number of circulating tumor cells,and PD-L1 expression or others.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The patients sign the written informed consent.
-
Women aged 18-75.
-
The pathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［ER-negative(IHC<1%), PR-negative(IHC<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］. Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.
-
PD-1/PD-L1positive or TMB≥5.
-
Prior therapy (adjuvant/neoadjuvant/advanced) must have included an anthracycline and/or a taxane in any combination or order and either in the early or metastatic disease setting unless contraindicated for a given patient.
-
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
-
The results of patient's blood tests are as follows:
• Hb≥90g/L; • Plt≥1009/L; • Serum albumin ≥3g/dL;• Neutrophils≥1.59/L; TSH≤ normal upper limit (ULN);• ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN); • TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome or liver metastasis subjects);• ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);• AKP≤ 2.5 ULN; • Renal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min
- Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment.
Exclusion Criteria:
-
The subjects had a central nervous system metastases with clinical symptoms.
-
Subjects with treatment history of PD-1 / PD-L1 inhibitors;
-
Peripheral neuropathy ≥ grade 2; Cardiac dysfunction, hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis and tuberculosis; Autoimmune diseases requiring systemic treatment, and a history of pneumonia (requiring corticosteroid treatment) or interstitial lung disease.
-
Pregnant or lactating women.
-
Other clinical trials of drugs were used in the first four weeks before the first dose.
-
The subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications.
-
Hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.).
-
Congenital or acquired immune deficiency (such as HIV infection);
-
Receive live vaccine within 4 weeks before or during the study period;
-
Patients who are allergic to or contraindicated to the experimental drugs.
-
Other malignant tumors in the past, except cervical cancer and non melanoma skin cancer, which have survived for 5 years without disease.
-
Subjects with any other diseases that are unfit for the treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Fifth Medical Center of PLA General Hospital | Beijing | Beijing | China | 100071 |
Sponsors and Collaborators
- Beijing 302 Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- breast-202204